TOP
Nav Bar
  1. General Info
  2. Effects Info
  3. Reference
Drug Details
01. General Information
Name Paclitaxel
PubChem CID 36314
Molecular Weight 853.9g/mol
Synonyms

33069-62-4, P88XT4IS4D, Paclitaxel, Taxol, Taxol A, Yewtaxan, Genaxol, Plaxicel, Abraxane, Ebetaxel, Genetaxyl, Capxol, Paxene, Onxol, Cyclopax, Genexol, Intaxel, Mitotax, TaxAlbin, OncoGel, Pacliex, Paxceed, EmPAC, Onxal, Zisu, Taxus stent, Taxus Liberte, ABI-007, Padexol, EndoTAG 1, LipoPac, Tocosol Paclitaxel, (-)-Paclitaxel, Nanoxel, Paclitaxol, Sindaxel, NSC-125973, Coroflex Please, Cypher select, Taxus Express, LEP-ETU, Genexol-PM, (NAB)-Paclitaxel, MBT 0206, Infinnium, Taxus, HSDB 6839, ABI 007, DHP 107, DHP-107, Abraxane I.V. Suspension, BMS 181339-01, BMS-181339-01, UNII-P88XT4IS4D, DRG-0190, Paclitaxel (Taxol), NK 105, NSC125973, Paclitaxel (taxus canadensis), QW 8184, CCRIS 8143, Liposome-entrapped paclitaxel easy-to-use, DTXSID9023413, CHEBI:45863, ABI-007 COMPONENT PACLITAXEL, IG 001, MFCD00869953, NK-105, 5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine, QW-8184, CHEMBL428647, DTXCID603413, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-9-(((2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl)oxy)-12-(benzoyloxy)-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-1H-7,11-methanocyclodeca[3,4]benzo[1,2-b]oxete-6,12b-diyl diacetate, nab-paclitaxel, ORAXOL COMPONENT PACLITAXEL, Paclitaxel [USAN:USP:INN:BAN], Abraxane (albumin-bound suspension), ABRAXANE COMPONENT PACLITAXEL, MBT-0206, ABI 007 COMPONENT PACLITAXEL, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, NCGC00164367-01, NAB-PACLITAXEL COMPONENT PACLITAXEL, 7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv., NSC 125973, PACLITAXEL (MART.), PACLITAXEL [MART.], PACLITAXEL (USP-RS), PACLITAXEL [USP-RS], (1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-bis(acetyloxy)-1,9-dihydroxy-15-{[(2R,3S)-2-hydroxy-3-phenyl-3-(phenylformamido)propanoyl]oxy}-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0^{3,10}.0^{4,7}]heptadec-13-en-2-yl benzoate, PACLITAXEL (EP MONOGRAPH), PACLITAXEL (USP IMPURITY), PACLITAXEL [EP MONOGRAPH], PACLITAXEL [USP IMPURITY], Anzatax, Cynviloq, PACLITAXEL (USP MONOGRAPH), PACLITAXEL [USP MONOGRAPH], Xorane, Paclitaxel (USAN:USP:INN:BAN), Bris Taxol, Taxol, Bris, SMR000857385, EndoTAG-1, SR-01000075350, paclitaxelum, Nanotaxel, Paclical, Pacligel, Paxoral, Paclitaxel?, Paclitaxel,(S), Abraxane (TN), (2alpha,5beta,7beta,10beta,13alpha)-4,10-bis(acetyloxy)-1,7-dihydroxy-13-({(2R,3S)-2-hydroxy-3-phenyl-3-[(phenylcarbonyl)amino]propanoyl}oxy)-9-oxo-5,20-epoxytax-11-en-2-yl benzoate, [diacetoxy-[(2R,3S)-3-benzamido-2-hydroxy-3-phenyl-propanoyl]oxy-dihydroxy-tetramethyl-oxo-[?]yl] benzoate, 4alpha,10beta-bis(acetyloxy)-13alpha-((2S,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyloxy)-1,7beta-dihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate, 4alpha,10beta-bis(acetyloxy)-13alpha-[(2S,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyloxy]-1,7beta-dihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate, Paclitaxel; 5beta,20-Epoxy-1,7beta-dihydroxy-9-oxotax-11-ene-2alpha,4,10beta,13alpha-tetrayl 4,10-diacetate 2-benzoate 13-[(2R,3S)-3-(benzoylamino)-2-hydroxy-3-phenylpropanoate]; Taxol; Docetaxel Anhydrous Impurity F; Docetaxel Impurity F, Taxol (Paclitaxel), CAS-33069-62-4, BMS-181339, Paclitaxel-SSMM-VIP, P-SSMM-VIP, PACLITAXEL [MI], PACLITAXEL [INN], PACLITAXEL [JAN], Prestwick3_000155, PACLITAXEL [HSDB], PACLITAXEL [USAN], PACLITAXELPACLITAXEL, TAXOL (TN), PACLITAXEL [VANDF], SCHEMBL3976, 3PPC5TL76P, Nova-12005, PACLITAXEL [WHO-DD], Paclitaxel, Taxus brevifolia, BIDD:PXR0046, BSPBio_000290, KBioGR_002509, KBioSS_002517, Paclitaxel (JAN/USP/INN), MLS002154218, MLS002695976, OAS-PAC-100, PACLITAXEL [EMA EPAR], BPBio1_000320, GTPL2770, MEGxp0_001940, Taxol (TN) (Bristol Meyers), PACLITAXEL [GREEN BOOK], PACLITAXEL [ORANGE BOOK], ACon1_002231, KBio2_002509, KBio2_005077, KBio2_007645, KBio3_002987, ANX-513, DHP-208, DTS-301, L01CD01, SDP-013, cMAP_000068, HMS2090D07, HMS2095O12, HMS2231A16, HMS3712O12, HY-B0015, MPI-5018, Tox21_112107, BDBM50001839, NSC745099, AKOS007930675, AKOS015969673, AKOS025312303, CCG-220155, CS-1145, DB01229, GS-6554, NSC-745099, NCGC00164367-02, NCGC00164367-03, NCGC00164367-04, NCGC00164367-05, NCGC00164367-10, Paclitaxel, From Taxus brevifolia, 95%, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-1,2a,3,4,4a,6,9,10,11,12,12a,12b-Dodecahydro-4,6,9,11,12,12b-hexahydroxy-4a,8,13,13-tetramethyl-7,11-methano-5H-cyclodeca(3,4)benz(1,2-b)oxet-5-one 6,12b-diacetate, 12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine, NCI60_000601, Paclitaxel, from Taxus yannanensis, powder, 1ST000431, PACLITAXEL IMPURITY L [EP IMPURITY], AB00513812, D00491, EN300-117275, M02242, N88686, AB00513812-02, AB00513812-03, Paclitaxel, Antibiotic for Culture Media Use Only, Q423762, 7,4]benz[1,2-b]oxete,benzenepropanoic acid deriv., Q-201533, SR-01000075350-1, SR-01000075350-3, SR-01000075350-6, SR-01000075350-7, SR-01000075350-9, BRD-K62008436-001-03-1, BRD-K62008436-001-05-6, BRD-K62008436-001-22-1, Paclitaxel, from semisynthetic (from Taxus sp.), >=97%, Paclitaxel, European Pharmacopoeia (EP) Reference Standard, Paclitaxel, from Taxus brevifolia, >=95% (HPLC), powder, Paclitaxel, United States Pharmacopeia (USP) Reference Standard, 12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine, Paclitaxel protein-bound particles for injectable suspension (albumin-bound), Paclitaxel, Pharmaceutical Secondary Standard; Certified Reference Material, Paclitaxel natural for peak identification, European Pharmacopoeia (EP) Reference Standard, (1S,2S,3R,4S,5R,7S,8S,10R,13S)-4,10-Diacetoxy-2-benzoyloxy-5,20-epoxy-1,7-dihydroxy-9-oxotax-11-en-13-yl (2R,3S)-3-benzoylamino-2-hydroxy-3-phenylpropionate, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-1,2a,3,4,4a,6,9,10,11,12,12a,12b-Dodecahydro 4,6,9,11,12,12b-hexahydroxy-4a,8,13,13-tetramethyl-7,11-methano 5Hcyclodeca(3,4)benz(1,2-b)oxet-5-one 6,12b-diacetate,, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-4,6,12b-Tris(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl (alphaR,betaS)-beta-(benzoylamino)-alpha-hydroxybenzenepropanoate, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl (aR,bS)-b-(benzoylamino)-a-hydroxybenzenepropanoate, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-9-(((2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl)oxy)-12-(benzoyloxy)-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-3,4,4a,5,6,9,10,11,12,12a-decahydro-1H-7,11-methanocyclodeca[3,4]benzo[1,2-b]oxete-6,12b(2aH)-diyl diacetate, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12, (2beta,5beta,7alpha,8alpha,10alpha,13alpha)-4,10-bis(acetyloxy)-1,7-dihydroxy-13-({(2R,3S)-2-hydroxy-3-phenyl-3-[(phenylcarbonyl)amino]propanoyl}oxy)-9-oxo-5,20-epoxytax-11-en-2-yl benzoate, ,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, ,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (alphaR,betaS)- (9CI), -cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, [2aR-[2aalpha,4beta,4abeta,6beta,9alpha(aR*,betaS*),11alpha,12alpha,12aalpha,12balpha]]-, [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-diacetyloxy-15-[(2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl]oxy-1,9-dihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate, [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-diacetyloxy-15-[(2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl]oxy-1,9-dihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl]benzoate, 1203669-79-7, 4,7beta,10beta-tris(acetyloxy)-13alpha-[[(2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl]oxy]-1-hydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate, 5-BETA,20-EPOXY-1,2-ALPHA,4,7-BETA,10-BETA,13-ALPHA-HEXAHYDROXY-TAX-11-EN-9-ONE 4,10-DIACETATE 2-BENZOATE 13-ESTER WITH (2R,3S)-N-BENZOYL-3-PHENYL-ISOSERINE, 5beta,20-Epoxy-1,2 alpha, 4,7beta, 10beta, 13alpha-hexahydroxy tax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R, 3S)-N-benzoyl-3-phenylisoserine, BENZENEPROPANOIC ACID, .BETA.-(BENZOYLAMINO)-.ALPHA.-HYDROXY-, (2AR,4S,4AS,6R,9S,11S,12S,12AR,12BS)-6,12B-BIS(ACETYLOXY)-12-(BENZOYLOXY)-2A,3,4,4A,5,6,9,10,11,12,12A,12B-DODECAHYDRO-4,11-DIHYDROXY-4A,8,13,13-TETRAMETHYL-5-OXO-7,11-METHANO-1H-CYCLODECA(3,4)BENZ(1,2-B)OXET-9-YL ESTER, (.ALPHA.R,.BETA.S)-, Benzenepropanoic acid, 6,12b-bis(acetyl oxy)-12-(benzoyloxy)- 2a,3,4,4a,5,6,9,10,11,12,12a,12b,- dodecahydro-4,11- dihydroxy-4a,8,13,13-tetramethyl-5-oxo- 7,11-methano- 1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, [2aR- [2a.alpha.,4.beta.,4a.beta.,6.beta.,9.alpha.(alpha. R*,.beta.S*),11.alpha.,12.alpha.,12a.alpha.,12b.alpha.]]-, Benzenepropanoic acid, b-(benzoylamino)-.alpha.-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (aR,bS)-, Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-4,6,12b-tris(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (alphaR,betaS)-, Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13, Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (alphaR,betaS)-, Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 4,6,12b-tris(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, [2aR-[2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha]]-, Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H, Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2a-alpha,4-beta,4a-beta,6-beta,9-alpha(alpha-R*,beta-S*),11-alpha,12-alpha,12a-alpha, 12b-alpha))-, Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-, Paclitaxel semi-synthetic for peak identification, European Pharmacopoeia (EP) Reference Standard, Paclitaxel semi-synthetic for system suitability, European Pharmacopoeia (EP) Reference Standard, TAX-11-EN-9-ONE, 5-BETA,20-EPOXY-1,2-ALPHA,4,7-BETA,10-BETA,13-ALPHA-HEXA-HYDROXY-, 4,10-DIACETATE 2-BENZOATE 13-ESTER WITH (2R,3S)-N-BENZOYL-3-PHENYLISOSERINE, Tax-11-en-9-one, 5beta,20-epoxy-1,2alpha,4,7beta,10beta,13alpha- hexahydroxy-, 4,10-diacetate 2-benzoate, 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine, TAX-11-EN-9-ONE, 5BETA,20-EPOXY-1,2ALPHA,4,7BETA,10BETA,13ALPHA-HEXAHYDROXY-, 4,10-DIACETATE 2-BENZOATE 13-ESTER WITH (2R,3S)-N-BENZOYL-3-PHENYLISOSERINE, Tax-11-en-9-one, 5beta,20-epoxy-1,2alpha,4,7beta,10beta,13alpha-hexahydroxy-, 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine (8CI), Tax-11-en-9-one, 5beta,20-epoxy-1,2alpha,4,7beta,10beta,13alpha-hexahydroxy-, 4,10-diacetate 2-benzoate, 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine, Tax-11-en-9-one,20-epoxy-1,2.alpha.,4,7.beta., 10.beta.,13.alpha.- hexahydroxy-, 4,10-diacetate 2- benzoate,13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
Drug Type Small molecule
Formula C₄₇H₅₁NO₁₄
SMILES CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C
InChI 1S/C47H51NO14/c1-25-31(60-43(56)36(52)35(28-16-10-7-11-17-28)48-41(54)29-18-12-8-13-19-29)23-47(57)40(61-42(55)30-20-14-9-15-21-30)38-45(6,32(51)22-33-46(38,24-58-33)62-27(3)50)39(53)37(59-26(2)49)34(25)44(47,4)5/h7-21,31-33,35-38,40,51-52,57H,22-24H2,1-6H3,(H,48,54)/t31-,32-,33+,35-,36+,37+,38-,40-,45+,46-,47+/m0/s1
InChIKey RCINICONZNJXQF-MZXODVADSA-N
CAS Number 33069-62-4
ChEMBL ID CHEMBL428647
ChEBI ID CHEBI:45863
TTD ID D0C4RB
Drug Bank ID DB01229
KEGG ID C07394
Toxicity Organism Test Type Route(Dose)
rat LD50 intraperitoneal(165 mg/kg)
mouse LD50 intraperitoneal(254 mg/kg)
rat LD50 oral(322 mg/kg)
Structure 2D-img
Download
2D MOL 3D MOL
03. Combinatorial Therapeutic Effect(s)
Synergistic Effect
Hide/Show
Enhancing Drug Efficacy
Hide/Show
Combination Pair ID: 570
Ref_5
Pair Name Zerumbone, Paclitaxel
Partner Name Zerumbone
Disease Info [ICD-11: 2C60] Breast cancer Investigative
Biological Phenomena Induction-->ROS-mediated oxidative stress
Gene Regulation Up-regulation Expression BAX hsa581
Down-regulation Expression BCL2 hsa596
Up-regulation Expression CASP7 hsa840
Up-regulation Expression CASP9 hsa842
In Vitro Model MCF-7 Invasive breast carcinoma of no special type Homo sapiens (Human) CVCL_0031
Result The prooxidant properties of zerumbone potentially resensitize breast cancer cells to PTX by enhancing intracellular ROS-mediated oxidative stress.
Combination Pair ID: 614
Ref_6
Pair Name Voacamine, Paclitaxel
Partner Name Voacamine
Disease Info [ICD-11: 2C73] Ovarian cancer Investigative
Biological Phenomena Induction-->Apoptosis
Gene Regulation Up-regulation Cleavage PARP1 hsa142
Down-regulation Expression RELA hsa5970
In Vitro Model A2780 Ovarian endometrioid adenocarcinoma Homo sapiens (Human) CVCL_0134
Result Our data show the specific effect of VOA which only works on drugs known to be substrates of P-gp.
Combination Pair ID: 1024
Ref_7
Pair Name Toosendanin, Paclitaxel
Partner Name Toosendanin
Disease Info [ICD-11: 2C60] Breast cancer Investigative
Biological Phenomena Induction-->Endoplasmic reticulum stress
Gene Regulation Down-regulation Expression ADORA2A hsa135
Down-regulation Expression CASP3 hsa836
Up-regulation Expression CDH1 hsa999
Down-regulation Expression CDH2 hsa1000
Down-regulation Expression CTNNB1 hsa1499
Down-regulation Expression PARP1 hsa142
Down-regulation Expression SNAI1 hsa6615
Down-regulation Expression TWIST1 hsa7291
Down-regulation Expression VIM hsa7431
In Vitro Model MDA-MB-231 Breast adenocarcinoma Homo sapiens (Human) CVCL_0062
BT-549 Invasive breast carcinoma of no special type Homo sapiens (Human) CVCL_1092
4T1 Malignant neoplasms of the mouse mammary gland Mus musculus (Mouse) CVCL_0125
In Vivo Model 2×10⁵ 4T1-fluc-red cells were inoculated in a mammary fat pat of each mouse.
Result The results suggest that combination of TSN and PTX is superior to PTX alone, suggesting that it may be a promising alternative adjuvant chemotherapy strategy for patients with TNBC, especially those with metastatic TNBC.
Combination Pair ID: 136
Ref_8
Pair Name Tectorigenin, Paclitaxel
Partner Name Tectorigenin
Disease Info [ICD-11: 2C73] Ovarian cancer Investigative
Gene Regulation Down-regulation Activity AKT1 hsa207
Down-regulation Expression BCL2 hsa596
Down-regulation Expression BCL-xL hsa598
Up-regulation Activity CASP3 hsa836
Up-regulation Activity CASP8 hsa841
Up-regulation Activity CASP9 hsa842
Down-regulation Expression CFLAR hsa8837
Down-regulation Phosphorylation CHUK hsa1147
Down-regulation Phosphorylation CHUK hsa1147
Down-regulation Expression COX2 hsa4513
Down-regulation Phosphorylation IKBKE hsa9641
Down-regulation Activity NFKB1 hsa4790
Down-regulation Phosphorylation NFKBIA hsa4792
Down-regulation Expression XIAP hsa331
In Vitro Model MPSC1 Low grade ovarian serous adenocarcinoma Homo sapiens (Human) CVCL_9822
A2780 Ovarian endometrioid adenocarcinoma Homo sapiens (Human) CVCL_0134
SK-OV-3 Ovarian serous cystadenocarcinoma Homo sapiens (Human) CVCL_0532
Result These data suggest that tectorigenin could sensitize paclitaxel-resistant human ovarian cancer cells through inactivation of the Akt/IKK/IκB/NFκB signaling pathway, and promise a new intervention to chemosensitize paclitaxel-induced cytotoxicity in ovarian cancer.
Combination Pair ID: 473
Ref_9
Pair Name Tea polyphenol, Paclitaxel
Partner Name Tea polyphenol
Disease Info [ICD-11: 2C73] Ovarian cancer Investigative
Biological Phenomena Induction-->Apoptosis
Gene Regulation Down-regulation Phosphorylation AKT1 hsa207
Up-regulation Expression BAX hsa581
Down-regulation Expression BCL2 hsa596
Up-regulation Cleavage CASP3 hsa836
Up-regulation Cleavage CASP9 hsa842
Up-regulation Expression CYCS hsa54205
In Vitro Model SK-OV-3 Ovarian serous cystadenocarcinoma Homo sapiens (Human) CVCL_0532
OVCAR-3 High grade ovarian serous adenocarcinoma Homo sapiens (Human) CVCL_0465
Result Our results showed that the combination of green tea and PTX could be more potent than the individual drug to induce cytotoxicity and apoptosis in ovarian cancer cells.
Combination Pair ID: 230
Ref_10
Pair Name Tanshinone I, Paclitaxel
Partner Name Tanshinone I
Disease Info [ICD-11: 2C73] Ovarian cancer Investigative
Biological Phenomena Induction-->Apoptosis
Gene Regulation Up-regulation Expression BAX hsa581
Down-regulation Expression BCL2 hsa596
Up-regulation Expression CDKN1A hsa1026
Up-regulation Expression CDKN2A hsa1029
In Vitro Model A2780 Ovarian endometrioid adenocarcinoma Homo sapiens (Human) CVCL_0134
ID8 Epithelial Ovarian Cancer Mus musculus (Mouse) CVCL_IU14
In Vivo Model The A2780 cells were injected bilaterally and subcutaneously into the flanks of the nude mice (100 µL, 2×10⁷ cells).
Result Natural compound Tan-I enhances the efficacy of ovarian cancer to Paclitaxel chemotherapy. The results will help to supply the potential clinical use of ovarian carcinoma cells.
Combination Pair ID: 139
Ref_11
Pair Name Silibinin, Paclitaxel
Partner Name Silibinin
Disease Info [ICD-11: 2C73] Ovarian cancer Investigative
Gene Regulation Up-regulation Expression CDKN1A hsa1026
Up-regulation Expression TP53 hsa7157
In Vitro Model SK-OV-3 Ovarian serous cystadenocarcinoma Homo sapiens (Human) CVCL_0532
Result Our results showed that combination of chemotherapy drugs of silibinin and paclitaxel can be more efficient in treatment of ovarian cancer cells.
Combination Pair ID: 100
Ref_12
Pair Name Silibinin, Paclitaxel
Partner Name Silibinin
Disease Info [ICD-11: 2B72] Gastric cancer Investigative
Biological Phenomena Induction-->Blockade of cell cycle in G2/M phase
Gene Regulation Up-regulation Expression BAX hsa581
Down-regulation Expression BCL2 hsa596
Up-regulation Cleavage CASP3 hsa836
Up-regulation Cleavage CASP8 hsa841
Down-regulation Expression CCNB1 hsa891
Down-regulation Expression CDC25C hsa995
Down-regulation Expression CDK1 hsa983
Up-regulation Expression FAS hsa355
Up-regulation Cleavage PARP1 hsa142
In Vitro Model BGC-823 Human papillomavirus-related cervical adenocarcinoma Homo sapiens (Human) CVCL_3360
SGC-7901 Human papillomavirus-related cervical adenocarcinoma Homo sapiens (Human) CVCL_0520
AGS Gastric adenocarcinoma Homo sapiens (Human) CVCL_0139
Result Synergistic apoptotic effects of silibinin in enhancing paclitaxel toxicity in human gastric cancer cell lines
Combination Pair ID: 319
Ref_13
Pair Name Rosmarinic acid, Paclitaxel
Partner Name Rosmarinic acid
Disease Info [ICD-11: 2C60] Breast cancer Investigative
Biological Phenomena Inhibition-->Angiogenesis
Gene Regulation Up-regulation Expression BAX hsa581
Down-regulation Expression BCL2 hsa596
Up-regulation Expression CASP3 hsa836
Down-regulation Expression NFKB1 hsa4790
Down-regulation Expression TNF hsa7124
Up-regulation Expression TP53 hsa7157
Down-regulation Expression VEGFA hsa7422
In Vivo Model Ascitic fluid of Ehrlich ascites carcinoma-infected mice was withdrawn then mixed with normal saline to form a suspen_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x0002_sion of 2×10⁶ cells and used as a source of Ehrlich carcinoma cells.
Result Rosmarinic acid exerted chemo-preventive and therapeutic potential alone or in combination with Paclitaxel. Moreover, rosmarinic acid targets numerous signaling pathways associated with breast cancer.
Combination Pair ID: 205
Ref_14
Pair Name Radix ranunculus temate saponins, Paclitaxel
Partner Name Radix ranunculus temate saponins
Disease Info [ICD-11: 2C73] Ovarian cancer Investigative
Gene Regulation Down-regulation Expression COL3A1 hsa1281
In Vitro Model A2780 Ovarian endometrioid adenocarcinoma Homo sapiens (Human) CVCL_0134
OVCAR-3 High grade ovarian serous adenocarcinoma Homo sapiens (Human) CVCL_0465
SK-OV-3 Ovarian serous cystadenocarcinoma Homo sapiens (Human) CVCL_0532
In Vivo Model A2780 cells (1×10⁶) were injected subcutaneously into the back of six-week-old BALB/c nu/nu female mice.
Result Combination of Taxol and RRTS may be a novel treatment strategy for patients with TR ovarian cancer.
Combination Pair ID: 1034
Ref_15
Pair Name Pulsatilla saponin D, Paclitaxel
Partner Name Pulsatilla saponin D
Disease Info [ICD-11: 2C25] Lung cancer Investigative
Gene Regulation Down-regulation Expression RAC3 hsa5881
In Vitro Model NCI-H1299 Lung large cell carcinoma Homo sapiens (Human) CVCL_0060
A-549 Lung adenocarcinoma Homo sapiens (Human) CVCL_0023
In Vivo Model A total of 5×10⁶ A549-PR and NCI-H1299-PR cells were subcutaneously injected near the dorsal flanks of the mice.
Result We found that treatment with paclitaxel combined with Pulsatilla saponin D, can overcome lung adenocarcinoma cell resistance to paclitaxel alone in cell culture and mouse xenograft models.
Combination Pair ID: 924
Ref_16
Pair Name Pristimerin, Paclitaxel
Partner Name Pristimerin
Disease Info [ICD-11: 2C25] Lung cancer Investigative
Gene Regulation Up-regulation Expression CDH1 hsa999
Down-regulation Expression CDH2 hsa1000
Down-regulation Expression VIM hsa7431
In Vitro Model A-549 Lung adenocarcinoma Homo sapiens (Human) CVCL_0023
In Vivo Model Xenograft inhibition of P@FPP NMs The A549 xenograft bearing nude mice (~ 80 mm3) were randomly divided into five groups (n = 4) and then intravenously injection of the following formulations: PBS, PRI, PTX, PRI in combination of PTX, and P@FPP NMs.
Result This active-targeting NMs provides a versatile nano-herb strategy for improving tumor-targeting of Chinese herbal extracts, which may help in the promotion of enhancing chemosensitivity of NSCLC in clinical applications.
Combination Pair ID: 367
Ref_17
Pair Name Polydatin, Paclitaxel
Partner Name Polydatin
Disease Info [ICD-11: 2B51] Osteosarcoma Investigative
Biological Phenomena Induction-->Blockade of cell cycle in S phase
Gene Regulation Up-regulation Expression ABCB1 hsa5243
Up-regulation Activity AKT1 hsa207
Up-regulation Cleavage CASP3 hsa836
Down-regulation Expression CCNA2 hsa890
Down-regulation Expression CDK2 hsa1017
Up-regulation Expression CDKN1A hsa1026
Up-regulation Expression MKI67 hsa4288
Down-regulation Expression MMP2 hsa4313
Down-regulation Expression MMP9 hsa4318
Up-regulation Cleavage PARP1 hsa142
In Vitro Model U2OS Osteosarcoma Homo sapiens (Human) CVCL_0042
MG-63 Osteosarcoma Homo sapiens (Human) CVCL_0426
Result Polydatin may enhance the chemosensitivity of osteosarcoma cells to paclitaxel.
Combination Pair ID: 10
Ref_18
Pair Name Piperlongumine, Paclitaxel
Partner Name Piperlongumine
Disease Info [ICD-11: 2B90] Colon cancer Investigative
Biological Phenomena Induction-->ROS mediated cell death
Gene Regulation Up-regulation Expression BAX hsa581
Down-regulation Expression BCL2 hsa596
Down-regulation Expression BIRC5 hsa332
Down-regulation Expression CDH2 hsa1000
Up-regulation Expression CDKN1A hsa1026
Down-regulation Expression CTNNB1 hsa1499
Down-regulation Expression FN1 hsa2335
Up-regulation Expression ROS1 hsa6098
Up-regulation Expression SMAD4 hsa4089
Up-regulation Expression TP53 hsa7157
Down-regulation Expression TWIST1 hsa7291
In Vitro Model Intestine 407 Human papillomavirus-related cervical adenocarcinoma Homo sapiens (Human) CVCL_1907
HCT 116 Colon carcinoma Homo sapiens (Human) CVCL_0291
Result Piperlongumine induces ROS mediated cell death and synergizes paclitaxel in human intestinal cancer cells
Combination Pair ID: 18
Ref_19
Pair Name Oxymatrine, Paclitaxel
Partner Name Oxymatrine
Disease Info [ICD-11: 2C25] Lung cancer Investigative
Biological Phenomena Induction-->Apoptosis
Gene Regulation Down-regulation Expression BCL2 hsa596
Down-regulation Expression BCL-xL hsa598
Down-regulation Expression BIRC2 hsa329
Down-regulation Expression BIRC3 hsa330
Down-regulation Expression BIRC5 hsa332
Up-regulation Cleavage CASP3 hsa836
Down-regulation Expression COX2 hsa4513
Down-regulation Phosphorylation JAK1 hsa3716
Down-regulation Phosphorylation JAK2 hsa3717
Down-regulation Expression MMP9 hsa4318
Up-regulation Cleavage PARP1 hsa142
Down-regulation Phosphorylation SRC hsa6714
Down-regulation Phosphorylation STAT5A KEGG ID N.A.
Down-regulation Expression VEGFA hsa7422
In Vitro Model NCI-H1299 Lung large cell carcinoma Homo sapiens (Human) CVCL_0060
A-549 Lung adenocarcinoma Homo sapiens (Human) CVCL_0023
In Vivo Model In a preclinical lung cancer mouse model, OMT when used in combination with paclitaxel produced a significant reduction in tumor volume.
Result Oxymatrine Attenuates Tumor Growth and Deactivates STAT5 Signaling in a Lung Cancer Xenograft Model
Combination Pair ID: 608
Ref_20
Pair Name Noscapine, Paclitaxel
Partner Name Noscapine
Disease Info [ICD-11: 2C82] Prostate cancer Investigative
Biological Phenomena Induction-->Apoptosis
Gene Regulation Down-regulation Expression AR hsa367
Up-regulation Expression BAX hsa581
Down-regulation Expression BCL2 hsa596
Down-regulation Expression KLK3 hsa354
In Vitro Model LNCaP Prostate carcinoma Homo sapiens (Human) CVCL_0395
PC-3 Prostate carcinoma Homo sapiens (Human) CVCL_0035
Result This study provides a novel concept of combination treatment of paclitaxel and noscapine to improve efficiency in human prostate cancer treatment.
Combination Pair ID: 61
Ref_21
Pair Name Luteolin, Paclitaxel
Partner Name Luteolin
Disease Info [ICD-11: 2C60] Breast cancer Investigative
Gene Regulation Down-regulation Expression CRIPTO hsa6997
Down-regulation Expression HMOX1 hsa3162
Down-regulation Expression NFE2L2 hsa4780
In Vitro Model MDA-MB-231 Breast adenocarcinoma Homo sapiens (Human) CVCL_0062
Result These findings suggest that luteolin treatment significantly attenuated the hallmarks of breast cancer stemness by downregulating Nrf2-mediated expressions. Luteolin constitutes a potential agent for use in cancer stemness-targeted breast cancer treatments.
Combination Pair ID: 409
Ref_22
Pair Name Luteolin, Paclitaxel
Partner Name Luteolin
Disease Info [ICD-11: 2B70] Esophageal cancer Investigative
Biological Phenomena Inhibition-->Epithelial-mesenchymal transition
Gene Regulation Up-regulation Expression BAX hsa581
Down-regulation Expression BCL2 hsa596
Up-regulation Cleavage CASP3 hsa836
Up-regulation Cleavage CASP9 hsa842
Up-regulation Expression CDH1 hsa999
Down-regulation Expression CDH2 hsa1000
Up-regulation Expression CLDN1 hsa9076
Up-regulation Phosphorylation MAP2K4 hsa6416
Up-regulation Phosphorylation MAP3K5 hsa4217
Up-regulation Phosphorylation MAPK8 hsa5599
Up-regulation Expression PMAIP1 hsa5366
Up-regulation Expression ROS1 hsa6098
Down-regulation Expression SIRT1 hsa23411
Down-regulation Expression VIM hsa7431
In Vitro Model TE-1 Esophageal squamous cell carcinoma Homo sapiens (Human) CVCL_1759
Eca-109 Esophageal squamous cell carcinoma Homo sapiens (Human) CVCL_6898
In Vivo Model EC109 cells(3×10⁶) were suspended in 200μl saline and injected subcutane-ously into the right forelimb of each mouse.
Result The molecular mechanism of inhibiting cell migration and EMT processes may be related to the inhibition of SIRT1, and the mechanism of apoptosis induction is associated with the reactive oxygen species (ROS)/c-Jun N-terminal kinase (JNK) pathway-mediated activation of mitochondrial apoptotic pathway.
Combination Pair ID: 88
Ref_23
Pair Name Hyperoside, Paclitaxel
Partner Name Hyperoside
Disease Info [ICD-11: 2C60] Breast cancer Investigative
Biological Phenomena Induction-->Apoptosis
Gene Regulation Up-regulation Expression BAX hsa581
Down-regulation Expression BCL2 hsa596
Up-regulation Activity CASP3 hsa836
Up-regulation Expression IL6 hsa3569
Down-regulation Expression RELA hsa5970
Down-regulation Activity TLR4 hsa7099
In Vitro Model MDA-MB-231 Breast adenocarcinoma Homo sapiens (Human) CVCL_0062
HCC1806 Breast squamous cell carcinoma, acantholytic variant Homo sapiens (Human) CVCL_1258
Result Hyperoside may elevate breast cancer cell sensitivity to paclitaxel by blocking TLR4 activation-mediated pro-inflammatory and pro-survival approaches, thereby endorsing its usefulness as a promising therapeutic combination to overcome chemosensitivity in breast cancer.
Combination Pair ID: 8
Ref_24
Pair Name Harmine, Paclitaxel
Partner Name Harmine
Disease Info [ICD-11: 2B72] Gastric cancer Investigative
Biological Phenomena Induction-->Apoptosis
Gene Regulation Up-regulation Expression BAX hsa581
Up-regulation Expression BAX hsa581
Down-regulation Expression BCL2 hsa596
Down-regulation Expression BIRC5 hsa332
Down-regulation Expression CDH2 hsa1000
Up-regulation Expression CDKN1A hsa1026
Down-regulation Expression COX2 hsa4513
Down-regulation Expression CTNNB1 hsa1499
Down-regulation Expression FN1 hsa2335
Down-regulation Expression NFKB1 hsa4790
Down-regulation Expression PCNA hsa5111
Up-regulation Expression ROS1 hsa6098
Up-regulation Expression SMAD4 hsa4089
Down-regulation Expression TNF hsa7124
Up-regulation Expression TP53 hsa7157
Down-regulation Expression TWIST1 hsa7291
In Vitro Model SGC-7901 Human papillomavirus-related cervical adenocarcinoma Homo sapiens (Human) CVCL_0520
In Vivo Model The mice were subcutaneously injected into the left axillary space with 0.1 ml of cell suspension containing 4-6×10⁶ SGC-7901 cells.
Result Harmine combined with paclitaxel inhibits tumor proliferation and induces apoptosis through down-regulation of cyclooxygenase-2 expression in gastric cancer
Combination Pair ID: 861
Ref_25
Pair Name Glabridin, Paclitaxel
Partner Name Glabridin
Disease Info [ICD-11: 2C60] Breast cancer Investigative
Biological Phenomena Inhibition-->Cell migration
Gene Regulation Up-regulation Expression BAX hsa581
Down-regulation Expression BCL2 hsa596
Up-regulation Cleavage CASP9 hsa842
Up-regulation Expression CDH1 hsa999
Down-regulation Expression CYP2C8 hsa1558
Down-regulation Expression CYP2J2 hsa1573
Up-regulation Expression OCLN hsa100506658
Down-regulation Expression VIM hsa7431
Down-regulation Expression ZEB1 hsa6935
In Vitro Model 4T1 Malignant neoplasms of the mouse mammary gland Mus musculus (Mouse) CVCL_0125
In Vivo Model The effect of glabridin on the pharmacokinetics of paclitaxel was assessed in healthy female Balb/C mice (25–30 g of body weight).
Result Glabridin plays dual action to intensify anti-metastatic potential of paclitaxel via impeding CYP2C8 in liver and CYP2J2/EETs in tumor of an orthotopic mouse model of breast cancer
Combination Pair ID: 250
Ref_26
Pair Name Ginsenoside Rg5, Paclitaxel
Partner Name Ginsenoside Rg5
Disease Info [ICD-11: 2C77] Cervical cancer Investigative
Biological Phenomena Induction-->Apoptosis
Gene Regulation Up-regulation Expression BAK1 hsa578
Up-regulation Expression BAX hsa581
Up-regulation Expression BBC3 hsa27113
Down-regulation Expression BCL2 hsa596
Down-regulation Expression BCL-xL hsa598
Up-regulation Expression BID hsa637
Down-regulation Expression BIRC3 hsa330
Up-regulation Activity CASP3 hsa836
Up-regulation Activity CASP9 hsa842
Down-regulation Expression MCL1 hsa4170
In Vitro Model HeLa Human papillomavirus-related cervical adenocarcinoma Homo sapiens (Human) CVCL_0030
HeLa/PTX Papillomavirus-related cervical adenocarcinoma Homo sapiens (Human) CVCL_HF87
Result Ginsenoside Rg5 Sensitizes Paclitaxel-Resistant Human Cervical-Adeno-Carcinoma Cells to Paclitaxel-And Enhances the Anticancer Effect of Paclitaxel
Combination Pair ID: 435
Ref_27
Pair Name Garcinol, Paclitaxel
Partner Name Garcinol
Disease Info [ICD-11: 2C60] Breast cancer Investigative
Biological Phenomena Induction-->Blockade of cell cycle in G2/M phase
Gene Regulation Down-regulation Expression BCL2 hsa596
Down-regulation Cleavage CASP3 hsa836
Down-regulation Expression CCNA2 hsa890
Up-regulation Expression CCNB1 hsa891
Down-regulation Expression CDC25A hsa993
Up-regulation Expression CDH1 hsa999
Down-regulation Expression CDK1 hsa983
Down-regulation Activity MMP2 hsa4313
Down-regulation Activity MMP9 hsa4318
Down-regulation Phosphorylation NFKBIA hsa4792
Down-regulation Expression PLA2G6 hsa8398
Up-regulation Expression PTGS1 hsa5742
Down-regulation Expression PTGS2 hsa5743
Down-regulation Phosphorylation RELA hsa5970
Down-regulation Expression SNAI1 hsa6615
Down-regulation Expression TIMP1 hsa7076
Down-regulation Expression TWIST1 hsa7291
Down-regulation Expression VEGFA hsa7422
Down-regulation Expression ZEB1 hsa6935
In Vitro Model 4T1 Malignant neoplasms of the mouse mammary gland Mus musculus (Mouse) CVCL_0125
In Vivo Model Balb/c mice were injected with 4T1-Luc cells (5×10⁴ in 0.2 ml of PBS) into the 4th mammary fat pad as described pre_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x0002_viously.
Result Garcinol sensitizes breast cancer cells to Taxol through the suppression of caspase-3/iPLA2 and NF-κB/Twist1 signaling pathways in a mouse 4T1 breast tumor model
Combination Pair ID: 492
Ref_28
Pair Name Gambogic Acid, Paclitaxel
Partner Name Gambogic Acid
Disease Info [ICD-11: 2C60] Breast cancer Investigative
Biological Phenomena Induction-->Apoptosis
Gene Regulation Up-regulation Expression BAX hsa581
Down-regulation Expression BCL2 hsa596
Up-regulation Cleavage CASP3 hsa836
Down-regulation Expression GLI1 hsa2735
Down-regulation Expression PTCH1 hsa5727
Down-regulation Expression SHH hsa6469
In Vitro Model MDA-MB-231 Breast adenocarcinoma Homo sapiens (Human) CVCL_0062
Result The combination of GA with paclitaxel may increase the antitumor effects on paclitaxel‑resistant TNBC via downregulating the SHH signaling pathway.
Combination Pair ID: 613
Ref_29
Pair Name Forskolin, Paclitaxel
Partner Name Forskolin
Disease Info [ICD-11: 2C25] Lung cancer Investigative
Biological Phenomena Induction-->Apoptosis
Gene Regulation Up-regulation Cleavage CASP3 hsa836
Down-regulation Expression CCNA1 hsa8900
Up-regulation Expression CDH1 hsa999
Up-regulation Cleavage PARP1 hsa142
Up-regulation Expression PSMD9 hsa5715
Down-regulation Expression VIM hsa7431
In Vitro Model NCI-H1299 Lung large cell carcinoma Homo sapiens (Human) CVCL_0060
A-549 Lung adenocarcinoma Homo sapiens (Human) CVCL_0023
Result Our findings encourage the design of future studies aimed at further exploring the Forskolin employment in NSCLC treatment.
Combination Pair ID: 399
Ref_30
Pair Name Curcumin, Paclitaxel
Partner Name Curcumin
Disease Info [ICD-11: 2C73] Ovarian cancer Investigative
Biological Phenomena Induction-->Apoptosis
Gene Regulation Down-regulation Expression BCL2 hsa596
Up-regulation Expression EGR1 hsa1958
Down-regulation Expression EP300 hsa2033
Down-regulation Expression MCL1 hsa4170
Down-regulation Activity NFKB1 hsa4790
Down-regulation Expression RELA hsa5970
Up-regulation Expression SNIP1 hsa79753
In Vitro Model SK-OV-3 Ovarian serous cystadenocarcinoma Homo sapiens (Human) CVCL_0532
MDAH 2774 Ovarian endometrioid adenocarcinoma Homo sapiens (Human) CVCL_0420
Result Curcumin reduces paclitaxel resistance in ovarian carcinoma cells by upregulating SNIP1 and inhibiting NFκB activity
Combination Pair ID: 327
Ref_31
Pair Name Caffeic acid, Paclitaxel
Partner Name Caffeic acid
Disease Info [ICD-11: 2C25] Lung cancer Investigative
Biological Phenomena Induction-->Apoptosis
Gene Regulation Up-regulation Expression BAX hsa581
Up-regulation Expression BID hsa637
Up-regulation Expression CASP3 hsa836
Up-regulation Expression CASP9 hsa842
Up-regulation Cleavage JUN hsa3725
Up-regulation Phosphorylation MAPK1 hsa5594
Up-regulation Phosphorylation MAPK3 hsa5595
Up-regulation Cleavage PARP1 hsa142
In Vitro Model NCI-H1299 Lung large cell carcinoma Homo sapiens (Human) CVCL_0060
In Vivo Model Xenograft models were established by subcutaneous injections of H1299 cells (5×10⁶) suspended in Matrigel, and the behavior and growth of tumors among the mice were observed daily.
Result Our results indicated that CA inhibited NSCLC H1299 cell growth by inducing apoptosis and CA and PTX combined produced a synergistic anti-cancer effect in H1299 cells.
Combination Pair ID: 779
Ref_32
Pair Name Caffeic acid phenethyl ester, Paclitaxel
Partner Name Caffeic acid phenethyl ester
Disease Info [ICD-11: 2C73] Ovarian cancer Investigative
Biological Phenomena Inhibition-->Cell migration
In Vitro Model OV7 Ovarian carcinoma Homo sapiens (Human) CVCL_2675
Result The simultaneous administration of PTX and CAPE enhanced the anti-migration activity of the chemotherapeutic used in this study.
Combination Pair ID: 988
Ref_33
Pair Name Baicalein, Paclitaxel
Partner Name Baicalein
Disease Info [ICD-11: 2C60] Breast cancer Investigative
In Vitro Model 4T1 Malignant neoplasms of the mouse mammary gland Mus musculus (Mouse) CVCL_0125
In Vivo Model 100 µl of 1×10⁵ 4T1 cells/mice having minimum passage number were injected subcutaneously at the right lower quadrant near the mammary gland into the animal abdomen.
Result Ratiometric codelivery of Paclitaxel and Baicalein loaded nanoemulsion for enhancement of breast cancer treatment.
Combination Pair ID: 563
Ref_34
Pair Name Arachidin-1, Paclitaxel
Partner Name Arachidin-1
Disease Info [ICD-11: 2C60] Breast cancer Investigative
Biological Phenomena Induced-->Mitochondrial oxidative stress
Gene Regulation Down-regulation Expression BIRC5 hsa332
Up-regulation Cleavage CASP7 hsa840
Up-regulation Expression TP53 hsa7157
In Vitro Model MDA-MB-231 Breast adenocarcinoma Homo sapiens (Human) CVCL_0062
MDA-MB-436 Invasive breast carcinoma Homo sapiens (Human) CVCL_0623
Result A-1 in combination with Pac inhibited cell proliferation, induced apoptosis through mitochondrial oxidative stress, and reduced TNBC spheroid growth. These findings underscore the impactful effects of the prenylated stilbenoid A-1 as a novel adjuvant for Pac chemotherapy in TNBC treatment.
Combination Pair ID: 528
Ref_35
Pair Name alpha-Hydroxylinoleic acid, Paclitaxel
Partner Name alpha-Hydroxylinoleic acid
Disease Info [ICD-11: 2C60] Breast cancer Investigative
Biological Phenomena Induction-->Autophagy
Gene Regulation Down-regulation Expression MAP1LC3A hsa84557
Up-regulation Expression MAP1LC3B hsa81631
Up-regulation Expression TRIB3 hsa57761
In Vitro Model MDA-MB-231 Breast adenocarcinoma Homo sapiens (Human) CVCL_0062
Result ABTL0812 enhances antitumor effect of paclitaxel and reverts chemoresistance in triple-negative breast cancer models.
Combination Pair ID: 526
Ref_36
Pair Name alpha-Hydroxylinoleic acid, Paclitaxel
Partner Name alpha-Hydroxylinoleic acid
Disease Info [ICD-11: 2C25] Lung cancer Investigative
Biological Phenomena Induction-->Autophagy
Gene Regulation Down-regulation Expression AKT1 hsa207
Down-regulation Expression MAP1LC3A hsa84557
Up-regulation Expression MAP1LC3B hsa81631
Up-regulation Phosphorylation PRKAA1 hsa5562
Up-regulation Expression TRIB3 hsa57761
In Vitro Model A-549 Lung adenocarcinoma Homo sapiens (Human) CVCL_0023
NCI-H1975 Lung adenocarcinoma Homo sapiens (Human) CVCL_1511
NCI-H157 Lung squamous cell carcinoma Homo sapiens (Human) CVCL_0463
NCI-H520 Lung squamous cell carcinoma Homo sapiens (Human) CVCL_1566
Result The safety profile of ABTL0812 and its good synergy with chemotherapy potentiate the therapeutic potential of current lines of treatment based on chemotherapy regimens, arising as a promising option for improving these patients therapeutic expectancy.
Combination Pair ID: 255
Ref_37
Pair Name Alpha-Hederin, Paclitaxel
Partner Name Alpha-Hederin
Disease Info [ICD-11: 2C25] Lung cancer Investigative
Biological Phenomena Induction-->Autophagy
Gene Regulation Up-regulation Cleavage CASP3 hsa836
Up-regulation Cleavage PARP1 hsa142
Up-regulation Expression ROS1 hsa6098
Up-regulation Expression SQSTM1 hsa8878
In Vitro Model NCI-H1299 Lung large cell carcinoma Homo sapiens (Human) CVCL_0060
NCI-H1650 Minimally invasive lung adenocarcinoma Homo sapiens (Human) CVCL_1483
Result Our findings suggest that α-Hed can increase the killing effect of Tax on NSCLC cells by promoting ROS accumulation, and that combining α-Hed with classical Tax represents a novel strategy for treating NSCLC.
Combination Pair ID: 269
Ref_38
Pair Name Alpha-Carotene, Paclitaxel
Partner Name Alpha-Carotene
Disease Info [ICD-11: 2C25] Lung cancer Investigative
Biological Phenomena Inhibition-->Cell metastasis
Gene Regulation Down-regulation Expression MMP2 hsa4313
Down-regulation Expression MMP9 hsa4318
Down-regulation Phosphorylation PTK2 hsa5747
Up-regulation Expression SERPINE1 hsa5054
Up-regulation Expression TIMP1 hsa7076
Up-regulation Expression TIMP2 hsa7077
In Vitro Model 3LL Malignant tumors of the mouse pulmonary system Mus musculus (Mouse) CVCL_5653
In Vivo Model Approximately 2×10⁶ LLC cells (0.1 ml/mouse) were injected (s.c.) into the right flank of mice.
Result We demonstrate that AC effectively inhibits LLC metastasis and suppresses lung metastasis in combination with taxol in LLC-bearing mice, suggesting that AC could be used as an anti-metastatic agent or as an adjuvant for anti-cancer drugs.
Combination Pair ID: 531
Ref_39
Pair Name Alliin, Paclitaxel
Partner Name Alliin
Disease Info [ICD-11: 2C60] Breast cancer Investigative
Biological Phenomena Induction-->Apoptosis
Gene Regulation Up-regulation Expression CFL1 hsa1072
Down-regulation Expression IPO9 hsa55705
In Vitro Model MCF-7 Invasive breast carcinoma of no special type Homo sapiens (Human) CVCL_0031
Result The data obtained in the present study allow us to conclude that CFL1 itself does not translocate actin into the cell nucleus but this transport requires the functional expression of IPO9.
Combination Pair ID: 485
Ref_40
Pair Name 10-Gingerol, Paclitaxel
Partner Name 10-Gingerol
Disease Info [ICD-11: 2C60] Breast cancer Investigative
Gene Regulation Down-regulation Expression ADRB2 hsa154
Up-regulation Expression BAX hsa581
Down-regulation Expression BCL2 hsa596
Down-regulation Expression MAPK1 hsa5594
Up-regulation Cleavage PARP1 hsa142
In Vitro Model MDA-MB-231 Breast adenocarcinoma Homo sapiens (Human) CVCL_0062
SUM159PT Breast pleomorphic carcinoma Homo sapiens (Human) CVCL_5423
In Vivo Model Human MDA-MB-231 cells (cell density: 5×10⁶ / 200 μL PBS) were injected into the breast fat pad of each mouse.
Result This data suggests that 10-G may be used as a new chemotherapeutic synergist in combination with paclitaxel to enhance anticancer activity. The potential value of ADRB2 as a target for improving chemotherapy sensitivity was also emphasized.
Combination Pair ID: 434
Ref_41
Pair Name [6]-Gingerol, Paclitaxel
Partner Name [6]-Gingerol
Disease Info [ICD-11: 2C60] Breast cancer Investigative
Biological Phenomena Inhibition-->Angiogenesis
Gene Regulation Up-regulation Expression BAX hsa581
Down-regulation Expression BCL2 hsa596
Up-regulation Activity CASP7 hsa840
Up-regulation Expression TP53 hsa7157
In Vitro Model MCF-7 Invasive breast carcinoma of no special type Homo sapiens (Human) CVCL_0031
Result Anticancer Efficacy of 6-Gingerol with Paclitaxel against Wild Type of Human Breast Adenocarcinoma
Reversing Drug Resistance
Hide/Show
Combination Pair ID: 17
Ref_42
Pair Name Raloxifene hydrochloride, Paclitaxel
Partner Name Raloxifene hydrochloride
Disease Info [ICD-11: 2C60] Breast cancer Investigative
Biological Phenomena Induction-->Blockade of cell cycle in G2/M phase
Gene Regulation Up-regulation Phosphorylation BCL2 hsa596
Up-regulation Phosphorylation CCNB1 hsa891
Up-regulation Phosphorylation CDC25C hsa995
Up-regulation Phosphorylation CDC25C hsa995
Up-regulation Phosphorylation CDK1 hsa983
In Vitro Model BCaP-37 Human papillomavirus-related cervical adenocarcinoma Homo sapiens (Human) CVCL_0164
Bats-72 Bats-72 was screened from ER- human breast cancer cell line BCap37 by time-stepwise and dose-stepwise increment exposure of paclitaxel as described previously / N.A.
Bads-200 Bads-200 was screened from ER- human breast cancer cell line BCap37 by time-stepwise and dose-stepwise increment exposure of paclitaxel as described previously / N.A.
Result Reversal effects of Raloxifene on paclitaxel resistance in 2 MDR breast cancer cells
Combination Pair ID: 1043
Ref_43
Pair Name Paeonol, Paclitaxel
Partner Name Paeonol
Disease Info [ICD-11: 2C60] Breast cancer Investigative
Gene Regulation Down-regulation Expression BCRP KEGG ID N.A.
Down-regulation Expression MRP1 KEGG ID N.A.
Down-regulation Expression P-gp KEGG ID N.A.
Down-regulation Expression transgelin 2 KEGG ID N.A.
In Vitro Model MCF-7/PTX Invasive breast carcinoma of no special type Homo sapiens (Human) CVCL_C5RS
Result These results not only provide insight into the potential application of paeonol to the reversal of paclitaxel resistance, thus facilitating the sensitivity of breast cancer chemotherapy, but also highlight a potential role of transgelin 2 in the development of paclitaxel resistance in breast cancer.
Combination Pair ID: 316
Ref_44
Pair Name Honokiol, Paclitaxel
Partner Name Honokiol
Disease Info [ICD-11: 2C25] Lung cancer Investigative
Biological Phenomena Induction-->Blockade of cell cycle in G2/M phase
Gene Regulation Up-regulation Expression ATF4 hsa468
Up-regulation Expression CDKN1A hsa1026
Up-regulation Expression DDIT3 hsa1649
Up-regulation Phosphorylation EIF2S1 hsa1965
Up-regulation Expression HSPA5 hsa3309
Up-regulation Expression MAP1LC3A hsa84557
Up-regulation Phosphorylation MAPK1 hsa5594
Up-regulation Phosphorylation MAPK8 hsa5599
Up-regulation Expression MCL1 hsa4170
Up-regulation Expression NKRF KEGG ID N.A.
Up-regulation Expression PMAIP1 hsa5366
Up-regulation Expression PSMD9 hsa5715
Up-regulation Expression PTEN hsa5728
Up-regulation Expression XBP1 hsa7494
In Vitro Model NCI-H1650 Minimally invasive lung adenocarcinoma Homo sapiens (Human) CVCL_1483
NCI-H1299 Lung large cell carcinoma Homo sapiens (Human) CVCL_0060
In Vivo Model H1299 cells were washed three times with cold PBS and suspended at a final concentration of 1×10⁷/ml in PBS. Next 100 µl cell suspensions were subcutaneously injected into the right flanks of the mice.
Result Synergistic killing effect of paclitaxel and honokiol in non-small cell lung cancer cells through paraptosis induction
Combination Pair ID: 985
Ref_45
Pair Name Fisetin, Paclitaxel
Partner Name Fisetin
Disease Info [ICD-11: 2C73] Ovarian cancer Investigative
Biological Phenomena Induction-->Apoptosis
Gene Regulation Down-regulation Expression ABCG2 hsa9429
Up-regulation Expression BAK1 hsa578
Down-regulation Expression BCL-xL hsa598
Up-regulation Activity CASP3 hsa836
In Vitro Model OVCAR-3 High grade ovarian serous adenocarcinoma Homo sapiens (Human) CVCL_0465
Caov-3 High grade ovarian serous adenocarcinoma Homo sapiens (Human) CVCL_0201
TOV-112D Ovarian endometrioid adenocarcinoma Homo sapiens (Human) CVCL_3612
SW626 Colon adenocarcinoma Homo sapiens (Human) CVCL_1725
Result Our study shows that PTX-FA and Fis-FA PBM NPs directly target platinum-resistant OvCa cells, induce cytotoxic/apoptotic effects, and reverse multi-drug resistance (MDR). These findings allow us to create new clinical applications using PTX-FA and Fis-FA combination nanoparticles to treat drug-resistant cancers.
Decreasing Drug Toxicity
Hide/Show
Combination Pair ID: 135
Ref_1
Pair Name Ononin, Paclitaxel
Partner Name Ononin
Disease Info [ICD-11: 2C25] Lung cancer Investigative
Biological Phenomena Induction-->Apoptosis
Gene Regulation Down-regulation Phosphorylation AKT1 hsa207
Down-regulation Expression CDH2 hsa1000
Down-regulation Expression MMP2 hsa4313
Down-regulation Expression MMP9 hsa4318
Down-regulation Expression MTOR hsa2475
Down-regulation Phosphorylation PIK3CB KEGG ID N.A.
Down-regulation Expression RELA hsa5970
In Vivo Model A549 cells (5×10⁹/mL) were inserted subcutaneously into each mouse's flank.
Result Our findings suggested that the therapeutic index of PTX-based chemotherapy could be improved by reducing toxicity with increasing antitumor capabilities when combined with ononin.
Combination Pair ID: 1025
Ref_2
Pair Name Lupeol, Paclitaxel
Partner Name Lupeol
Disease Info [ICD-11: 2B66.0] Oral squamous cell carcinoma Investigative
Biological Phenomena Induction-->Vasculogenic mimicry
Gene Regulation Up-regulation Expression BAX hsa581
Down-regulation Expression BCL2 hsa596
Up-regulation Expression CDH1 hsa999
Down-regulation Expression CDH5 hsa1003
Down-regulation Expression EPHA2 hsa1969
Down-regulation Expression HIF1A hsa3091
Down-regulation Expression MMP2 hsa4313
Down-regulation Expression PROM1 hsa8842
Down-regulation Expression SNAI1 hsa6615
Down-regulation Expression TWIST1 hsa7291
Down-regulation Expression VIM hsa7431
In Vitro Model UPCI-SCC-154 Tongue squamous cell carcinoma Homo sapiens (Human) CVCL_2230
UPCI-SCC-090 Tongue squamous cell carcinoma Homo sapiens (Human) CVCL_1899
Result Our findings elucidated mechanistic underpinning of hypoxia induced Laminin-5γ2 driven VM formation highlighting that Lupeol-Paclitaxel combination may serve as novel therapeutic intervention in perturbation of VM in human OSCC.
Combination Pair ID: 446
Ref_3
Pair Name Corilagin, Paclitaxel
Partner Name Corilagin
Disease Info [ICD-11: 2C73] Ovarian cancer Investigative
Biological Phenomena Inhibition-->Glycolysis
Gene Regulation Down-regulation Expression CD44 hsa960
Down-regulation Phosphorylation MAPK1 hsa5594
Down-regulation Expression SNAI1 hsa6615
Down-regulation Expression STAT3 hsa6774
In Vitro Model KOV3.ip1 Ovarian serous cystadenocarcinoma Homo sapiens (Human) CVCL_0C84
HEY High grade ovarian serous adenocarcinoma Homo sapiens (Human) CVCL_0297
HO-8910 Human papillomavirus-related cervical adenocarcinoma Homo sapiens (Human) CVCL_6868
Result Our observations indicate that corilagin sensitized epithelial ovarian cancer cells to paclitaxel and carboplatin treatment by primarily inhibiting Snail-glycolysis pathways. Corilagin is a herbal medicine with low toxic effects to normal cells, particularly hepatoprotective, and may be an ideal complimentary medicine when combined with highly toxic chemotherapeutic agents.
Combination Pair ID: 997
Ref_4
Pair Name Chrysin, Paclitaxel
Partner Name Chrysin
Disease Info [ICD-11: 2A00-2F9Z] Solid tumour or cancer Investigative
Biological Phenomena Induction-->Apoptosis
Gene Regulation Up-regulation Expression BAX hsa581
Down-regulation Expression BCL2 hsa596
Up-regulation Expression CASP3 hsa836
Down-regulation Expression CAT hsa847
Up-regulation Expression COX2 hsa4513
Down-regulation Expression GPX3 hsa2878
Down-regulation Expression GSTK1 hsa373156
Up-regulation Expression HAVCR1 hsa26762
Up-regulation Expression NFKB1 hsa4790
Down-regulation Expression SOD1 hsa6647
In Vivo Model Thirty-five male Sprague-Dawley rats were divided into five groups (n = 7): Group I (normal control), Group II (CR alone at a dose of 50 mg/kg), Group III (Pax at a dose of 2 mg/kg), Group IV (Pax+CR 25), and Group V (Pax+CR 50).
Result CR exhibited the ability to reduce oxidative DNA damage, exert anti-apoptotic and anti-inflammatory properties, and mitigate the toxic effects of Pax-induced hepatorenal toxicity.
04. Reference
No. Title Href
1 Antitumor Effects of Ononin by Modulation of Apoptosis in Non-Small-Cell Lung Cancer through Inhibiting PI3K/Akt/mTOR Pathway. Oxid Med Cell Longev. 2022 Dec 27;2022:5122448. doi: 10.1155/2022/5122448. Click
2 Lupeol and Paclitaxel cooperate in hindering hypoxia induced vasculogenic mimicry via suppression of HIF-1α-EphA2-Laminin-5γ2 network in human oral cancer. J Cell Commun Signal. 2023 Sep;17(3):591-608. doi: 10.1007/s12079-022-00693-z. Click
3 Corilagin sensitizes epithelial ovarian cancer to chemotherapy by inhibiting Snail‑glycolysis pathways. Oncol Rep. 2017 Oct;38(4):2464-2470. doi: 10.3892/or.2017.5886. Click
4 Chrysin attenuates paclitaxel-induced hepatorenal toxicity in rats by suppressing oxidative damage, inflammation, and apoptosis. Life Sci. 2023 Nov 1;332:122096. doi: 10.1016/j.lfs.2023.122096. Click
5 Zerumbone-induced reactive oxygen species-mediated oxidative stress re-sensitizes breast cancer cells to paclitaxel. Biotechnol Appl Biochem. 2023 Feb;70(1):28-37. doi: 10.1002/bab.2326. Click
6 A natural product, voacamine, sensitizes paclitaxel-resistant human ovarian cancer cells. Toxicol Appl Pharmacol. 2022 Jan 1;434:115816. doi: 10.1016/j.taap.2021.115816. Click
7 Synergistic Anti-Tumor Effect of Toosendanin and Paclitaxel on Triple-Negative Breast Cancer via Regulating ADORA2A-EMT Related Signaling. Adv Biol (Weinh). 2023 Aug;7(8):e2300062. doi: 10.1002/adbi.202300062. Click
8 Tectorigenin sensitizes paclitaxel-resistant human ovarian cancer cells through downregulation of the Akt and NFκB pathway. Carcinogenesis. 2012 Dec;33(12):2488-98. doi: 10.1093/carcin/bgs302. Click
9 Synergistic effects of green tea extract and paclitaxel in the induction of mitochondrial apoptosis in ovarian cancer cell lines. Gene. 2021 Jun 30;787:145638. doi: 10.1016/j.gene.2021.145638. Click
10 Natural compound Tan-I enhances the efficacy of Paclitaxel chemotherapy in ovarian cancer. Ann Transl Med. 2020 Jun;8(12):752. doi: 10.21037/atm-20-4072. Click
11 Enhancement of anticancer activity by silibinin and paclitaxel combination on the ovarian cancer. Artif Cells Nanomed Biotechnol. 2018 Nov;46(7):1483-1487. doi: 10.1080/21691401.2017.1374281. Click
12 Synergistic apoptotic effects of silibinin in enhancing paclitaxel toxicity in human gastric cancer cell lines. Mol Med Rep. 2018 Aug;18(2):1835-1841. doi: 10.3892/mmr.2018.9129. Click
13 Rosmarinic acid suppresses inflammation, angiogenesis, and improves paclitaxel induced apoptosis in a breast cancer model via NF3 κB-p53-caspase-3 pathways modulation. J Appl Biomed. 2021 Dec;19(4):202-209. doi: 10.32725/jab.2021.024. Click
14 Radix ranunculus temate saponins sensitizes ovarian cancer to Taxol via upregulation of miR-let-7b. Exp Ther Med. 2022 May;23(5):315. doi: 10.3892/etm.2022.11244. Click
15 Pulsatilla saponin D regulates ras-related C3 botulinum toxin substrate 3 (RAC3) to overcome resistance to paclitaxel in lung adenocarcinoma cells. BMC Cancer. 2024 Jan 10;24(1):55. doi: 10.1186/s12885-024-11841-6. Click
16 Accurate delivery of pristimerin and paclitaxel by folic acid-linked nano-micelles for enhancing chemosensitivity in cancer therapy. Nano Converg. 2022 Nov 24;9(1):52. doi: 10.1186/s40580-022-00343-5. Click
17 Polydatin enhances the chemosensitivity of osteosarcoma cells to paclitaxel. J Cell Biochem. 2019 Oct;120(10):17481-17490. doi: 10.1002/jcb.29012. Click
18 Piperlongumine induces ROS mediated cell death and synergizes paclitaxel in human intestinal cancer cells. Biomed Pharmacother. 2020 Aug;128:110243. doi: 10.1016/j.biopha.2020.110243. Click
19 Oxymatrine Attenuates Tumor Growth and Deactivates STAT5 Signaling in a Lung Cancer Xenograft Model. Cancers (Basel). 2019 Jan 7;11(1):49. doi: 10.3390/cancers11010049. Click
20 Synergistic Anticancer Effect of Paclitaxel and Noscapine on Human Prostate Cancer Cell Lines. Iran J Pharm Res. 2017 Fall;16(4):1432-1442. Click
21 Luteolin Inhibits Breast Cancer Stemness and Enhances Chemosensitivity through the Nrf2-Mediated Pathway. Molecules. 2021 Oct 26;26(21):6452. doi: 10.3390/molecules26216452. Click
22 Luteolin combined with low-dose paclitaxel synergistically inhibits epithelial-mesenchymal transition and induces cell apoptosis on esophageal carcinoma in vitro and in vivo. Phytother Res. 2021 Nov;35(11):6228-6240. doi: 10.1002/ptr.7267. Click
23 Administration with hyperoside sensitizes breast cancer cells to paclitaxel by blocking the TLR4 signaling. Mol Cell Probes. 2020 Oct;53:101602. doi: 10.1016/j.mcp.2020.101602. Click
24 Harmine combined with paclitaxel inhibits tumor proliferation and induces apoptosis through down-regulation of cyclooxygenase-2 expression in gastric cancer. Oncol Lett. 2016 Aug;12(2):983-988. doi: 10.3892/ol.2016.4696. Click
25 Glabridin plays dual action to intensify anti-metastatic potential of paclitaxel via impeding CYP2C8 in liver and CYP2J2/EETs in tumor of an orthotopic mouse model of breast cancer. Chem Biol Interact. 2023 Sep 1;382:110605. doi: 10.1016/j.cbi.2023.110605. Click
26 Ginsenoside Rg5 Sensitizes Paclitaxel-Resistant Human Cervical-Adeno-Carcinoma Cells to Paclitaxel-And Enhances the Anticancer Effect of Paclitaxel. Genes (Basel). 2022 Jun 24;13(7):1142. doi: 10.3390/genes13071142. Click
27 Garcinol sensitizes breast cancer cells to Taxol through the suppression of caspase-3/iPLA2 and NF-κB/Twist1 signaling pathways in a mouse 4T1 breast tumor model. Food Funct. 2017 Mar 22;8(3):1067-1079. doi: 10.1039/c6fo01588c. Click
28 Gambogic acid increases the sensitivity to paclitaxel in drug‑resistant triple‑negative breast cancer via the SHH signaling pathway. Mol Med Rep. 2019 Nov;20(5):4515-4522. doi: 10.3892/mmr.2019.10697. Click
29 Forskolin affects proliferation, migration and Paclitaxel-mediated cytotoxicity in non-small-cell lung cancer cell lines via adenylyl cyclase/cAMP axis. Eur J Cell Biol. 2023 Jun;102(2):151292. doi: 10.1016/j.ejcb.2023.151292. Click
30 Curcumin reduces paclitaxel resistance in ovarian carcinoma cells by upregulating SNIP1 and inhibiting NFκB activity. Biochem Pharmacol. 2023 Jun;212:115581. doi: 10.1016/j.bcp.2023.115581. Click
31 Synergistic Anticancer Activity of Combined Use of Caffeic Acid with Paclitaxel Enhances Apoptosis of Non-Small-Cell Lung Cancer H1299 Cells in Vivo and in Vitro. Cell Physiol Biochem. 2018;48(4):1433-1442. doi: 10.1159/000492253. Click
32 Caffeic Acid Phenethyl Ester (CAPE) Synergistically Enhances Paclitaxel Activity in Ovarian Cancer Cells. Molecules. 2023 Aug 1;28(15):5813. doi: 10.3390/molecules28155813. Click
33 Ratiometric codelivery of Paclitaxel and Baicalein loaded nanoemulsion for enhancement of breast cancer treatment. Int J Pharm. 2023 Aug 25;643:123209. doi: 10.1016/j.ijpharm.2023.123209. Click
34 Arachidin-1, a Prenylated Stilbenoid from Peanut, Enhances the Anticancer Effects of Paclitaxel in Triple-Negative Breast Cancer Cells. Cancers (Basel). 2023;15(2):399. Published 2023 Jan 7. doi:10.3390/cancers15020399 Click
35 ABTL0812 enhances antitumor effect of paclitaxel and reverts chemoresistance in triple-negative breast cancer models. Cancer Commun (Lond). 2022 Jun;42(6):567-571. doi: 10.1002/cac2.12282. Click
36 The novel proautophagy anticancer drug ABTL0812 potentiates chemotherapy in adenocarcinoma and squamous nonsmall cell lung cancer. Int J Cancer. 2020 Aug 15;147(4):1163-1179. doi: 10.1002/ijc.32865. Click
37 The Novel Autophagy Inhibitor Alpha-Hederin Promoted Paclitaxel Cytotoxicity by Increasing Reactive Oxygen Species Accumulation in Non-Small Cell Lung Cancer Cells. Int J Mol Sci. 2018 Oct 18;19(10):3221. doi: 10.3390/ijms19103221. Click
38 Alpha-carotene inhibits metastasis in Lewis lung carcinoma in vitro, and suppresses lung metastasis and tumor growth in combination with taxol in tumor xenografted C57BL/6 mice. J Nutr Biochem. 2015 Jun;26(6):607-15. doi: 10.1016/j.jnutbio.2014.12.012. Click
39 Downregulation of importin-9 protects MCF-7 cells against apoptosis induced by the combination of garlic-derived alliin and paclitaxel. Oncol Rep. 2016 May;35(5):3084-93. doi: 10.3892/or.2016.4628. Click
40 10-Gingerol Enhances the Effect of Taxol in Triple-Negative Breast Cancer via Targeting ADRB2 Signaling. Drug Des Devel Ther. 2023 Jan 20;17:129-142. doi: 10.2147/DDDT.S390602. Click
41 Anticancer Efficacy of 6-Gingerol with Paclitaxel against Wild Type of Human Breast Adenocarcinoma. Molecules. 2022 Apr 22;27(9):2693. doi: 10.3390/molecules27092693. Click
42 Reversal effects of Raloxifene on paclitaxel resistance in 2 MDR breast cancer cells. Cancer Biol Ther. 2015;16(12):1794-801. doi: 10.1080/15384047.2015.1095409. Click
43 Paeonol reverses paclitaxel resistance in human breast cancer cells by regulating the expression of transgelin 2. Phytomedicine. 2014;21(7):984-991. doi:10.1016/j.phymed.2014.02.012 Click
44 Synergistic killing effect of paclitaxel and honokiol in non-small cell lung cancer cells through paraptosis induction. Cell Oncol (Dordr). 2021 Feb;44(1):135-150. doi: 10.1007/s13402-020-00557-x. Click
45 The effect of paclitaxel- and fisetin-loaded PBM nanoparticles on apoptosis and reversal of drug resistance gene ABCG2 in ovarian cancer. J Ovarian Res. 2023 Nov 21;16(1):220. doi: 10.1186/s13048-023-01308-w. Click
It has been 46344 visits since 2024.08
If you find any error in data or bug in web service, please kindly report it to Dr. Zhang
TOP